A2 Biotherapeutics, Inc.

The week before the annual J.P. Morgan Healthcare Conference always brings a flurry of new venture capital financings and the tradition continued in 2025, including Aviceda Therapeutics with a $207.5m

It is too soon for the Pitchbook and National Venture Capital Association (NVCA) Venture Monitor report detailing fourth quarter 2022 VC investment, including a breakdown of biopharmaceutical fundra

Medical Device Acquisitions The first quarter featured 24 device M&A transactions, 17 of which had disclosed values that together totaled $10.2bn, versus the fourth quarter of 2020, when 21 deals tota

Venture capital fundraising by biopharmaceutical companies in 2020 totaled $19.5bn during the first three quarters of 2020, which beats the full year 2019 total of $17.4bn and is on track to surpass t